Sunshine Biopharma Files 8-K: Accountant Change & Exhibits
Ticker: SBFMW · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma Inc. (SBFMW) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, accounting, filing
TL;DR
Sunshine Biopharma changed accountants and filed exhibits on 9/24.
AI Summary
Sunshine Biopharma Inc. filed an 8-K on September 24, 2025, reporting changes in its certifying accountant and filing financial statements and exhibits. The company, incorporated in Colorado with its fiscal year ending December 31, is located at 333 Las Olas Way, Fort Lauderdale, FL.
Why It Matters
This filing indicates a change in the company's auditor, which can sometimes signal internal accounting reviews or a shift in financial oversight.
Risk Assessment
Risk Level: low — The filing is a standard procedural update regarding accounting and exhibits, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 001-41282 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-5566275 — EIN (Employer Identification Number for the company.)
Key Players & Entities
- Sunshine Biopharma Inc. (company) — Registrant
- September 24, 2025 (date) — Date of earliest event reported
- Colorado (jurisdiction) — State of incorporation
- 333 Las Olas Way, Fort Lauderdale, FL (address) — Business and mail address
FAQ
What is the primary reason for this 8-K filing?
The primary reasons are changes in the registrant's certifying accountant and the filing of financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on September 24, 2025.
In which state was Sunshine Biopharma Inc. incorporated?
Sunshine Biopharma Inc. was incorporated in Colorado.
What is the business address of Sunshine Biopharma Inc.?
The business address is 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 754 words · 3 min read · ~3 pages · Grade level 13.4 · Accepted 2025-09-30 16:05:35
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Filing Documents
- sunshine_8k.htm (8-K) — 29KB
- 0001683168-25-007338.txt ( ) — 233KB
- sbfm-20250924.xsd (EX-101.SCH) — 3KB
- sbfm-20250924_def.xml (EX-101.DEF) — 26KB
- sbfm-20250924_lab.xml (EX-101.LAB) — 36KB
- sbfm-20250924_pre.xml (EX-101.PRE) — 25KB
- sunshine_8k_htm.xml (XML) — 5KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant Effective September 24, 2025, Sunshine Biopharma Inc. (the "Company"), dismissed Bush & Associates CPA LLC ("Bush & Associates"), as its independent registered public accounting firm and retained M&K CPAS, PLLC ("M&K") as its independent auditor. The decision to dismiss Bush & Associates and retain M&K was approved by the unanimous consent of the Company's board of directors and the Company's audit committee. During the Company's fiscal years ended December 31, 2023 and 2024 and the subsequent interim period through September 24 , 2025, there were (i) no disagreements with Bush & Associates on any matter of accounting principles or practices, financial statement disclosure, or auditing scope of procedures, which disagreements, if not resolved to the satisfaction of Bush & Associates, would have caused Bush & Associates to make reference to the subject matter of the disagreements in connection with its reports on the Company's financial statements, and (ii) no "reportable events," as defined in Item 304(a)(1)(v) of Regulation S-K. The audit reports of Bush & Associates on the Company's financial statements as of and for the years ended December 31, 2023 and 2024, did not contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. The Company provided Bush & Associates with a copy of the disclosures in this Current Report on Form 8-K and requested that Bush & Associates furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether Bush & Associates agrees with the above statements. As of the date of the filing of this report, no such letter has been received. The Company will file such letter following receipt by amendment to this report. During the Company's two most recent fiscal years and in the subsequent interim period through September 24, 2025, neither the Company nor anyone
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No . Description 16.1 Letter from Bush & Associates (to be filed by amendment) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 30, 2025 SUNSHINE BIOPHARMA INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3